Oxygen Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--

Oxygen Biotherapeutics, Inc. OXBT, a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that John Kelley, Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference at Le Parker Meridien in New York on Wednesday, August 13, 2014, at 1:20 p.m. ET.

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investors section of the Company's website at www.oxybiomed.com.

An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Oxygen Biotherapeutics

Oxygen Biotherapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The company has North American rights to levosimendan and is currently evaluating it in a Phase 3 trial for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The FDA has granted Fast Track status for levosimendan and has granted a Special Protocol Assessment for the Phase 3 trial protocol. The company has also developed Oxycyte^®, a proprietary perfluorocarbon therapeutic oxygen carrier, currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the company's control that could lead to delays in the clinical study, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in the company's filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on July 29, 2014, as well as its other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.